To the Editor:
We would like to discuss the article recently published in The Journal of Rheumatology, entitled “Immunoglobulin A Vasculitis Following COVID-19: A French Multicenter Case Series” by Ramdani et al.1 This case series of individuals who developed IgA vasculitis (IgAV) after contracting SARS-CoV-2 describes the formation of IgAV shortly after coronavirus disease 2019 (COVID-19) infection; however, it was unable to completely rule out a coincidental connection between these 2 events.1 In most patients, the SARS-CoV-2 infection was paucisymptomatic. The authors advised reverse transcription-PCR tests to identify COVID-19 in patients who had no obvious IgAV triggers.1
Given that comorbidity can be challenging to manage, it is imperative to investigate any potential COVID-19 vaccine issues.2 Typically, this is not a good alternative if a clinical problem arises following the vaccination. Before receiving a vaccination, it is crucial to rule out any underlying diseases or comorbidities that may potentially lead to a clinical problem. Patients with SARS-CoV-2 may not be identified because they show no symptoms. If there is a hidden comorbidity, it might be easily mistaken to be a negative effect of the immunization.3 Further, recent research4 has associated underlying genetic variance with immune responses to the COVID-19 vaccine among recipients. Future studies should consider the many genetic background elements.
Footnotes
The authors declare no conflicts of interest relevant to this article.
- Copyright © 2023 by the Journal of Rheumatology
